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As a series of endeavors to establish suitablemeasures for the sounddevelopment of regenerativemedicine
using human stem cell-based products, we studied scientiﬁc principles, concepts and basic technical el-
ements to ensure the quality and safety of therapeutic products derived from allogeneic human induced
pluripotent stem cells (iPS cells) or iPS cell-like cells, taking into consideration scientiﬁc and technological
advances, ethics, regulatory rationale, and international trends in human stem cell-derived products. This
led to the development of the Japanese ofﬁcial Notiﬁcation No. 0907-5, “Guideline on Ensuring the Quality
and Safety of Pharmaceuticals and Medical Devices Derived from the Processing of Allogeneic Human
Induced Pluripotent Stem(-Like) Cells,” issued by Pharmaceuticals and Food Safety Bureau, Ministry of
Health, Labour andWelfare of Japan, on September 7, 2012. The present paper addresses various aspects of
products derived from allogeneic human iPS cells (or iPS cell-like cells), in addition to similar points to
consider that are described previously for allogeneic human stem cell-based products. Major additional
points include 1) possible existence of allogeneic human iPS cell-like cells that are different from iPS cells in
speciﬁc biological features; 2) the use of allogeneic human iPS(-like) cells as appropriate startingmaterials
for regenerativemedicine, where necessary and signiﬁcant; 3) establishment of an allogeneic human iPS(-
like) cell line and its characterization; 4) establishment of well-characterized stable cell banks and relevant
intermediate cell products, if necessary; 5) concerns about the presence of undifferentiated cells in ﬁnal
products; such cells may cause ectopic tissue formation and/or tumorigenesis; and 6) concerns about
undesirable immunological reactions that may be caused by the ﬁnal products. The ultimate goal of this
guidance is to provide suitable medical opportunities as soon as possible to the patients with severe dis-
eases that are difﬁcult to treat with conventional modalities.
© 2015, The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).s a distinct product from both conventional pharmaceuticals and medical devices according to the revised Pharma-
nd Medical Devices, and Other Therapeutic Products Act. (Akinori Hara, Daisaku Sato, and Yasuyuki Sahara: New
Therapies in Japan. Therapeutic Innovation & Regulatory Science. 2014; 48(6): 681e688.)
.jp, hayakawatakao@gmail.com (T. Hayakawa).
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The details of the series of the present studies have been
described in the previous papers [1e3]. The present paper provides
a summary of points that are closely related to those in the ﬁrst
paper.
Development of regenerative medicine using cell-based
products derived from the processing of human cells and tis-
sues is keenly anticipated in Japan because of the difﬁculties in
securing human organs and tissues in our country. With break-
throughs in technology and advances in research, more and more
people are hopeful that this medical technology using novel cell-
based products will result in the development of effective
therapies.
In Japan, translational research on regenerative medicine is
advancing rapidly. In particular, much work has been done on
product development using human stem cells, i.e., somatic stem
cells such as mesenchymal stem cells, embryonic stem (ES) cells,
and induced pluripotent stem (iPS) cells. Thus, there is an urgent
need to prepare relevant guidelines on evaluation of products ex-
pected to be developed in the near future. Identifying the technical,
medical, and ethical conditions necessary for utilizing various types
of stem cells at an early stage of development is vital for their rapid
application in clinical settings.
In the ﬁscal year 2008, the Japanese Ministry of Health, Labour
and Welfare decided to form a panel of experts: the “Study Group
on Ensuring the Quality and Safety of Pharmaceuticals and Medical
Devices Derived from Processing of Human Stem Cells.” The panel
was established as a scientiﬁc research project of the Ministry of
Health, Labour and Welfare of Japan and has subsequently been
chaired by Dr. Takao Hayakawa.
The objective of the study group is to promote the sound
development of products derived from human stem cells by
investigating scientiﬁc and technological advances, their ethical
validity, the regulatory rationale, and international trends in hu-
man stem cell-derived products and to establish and implement
appropriate safety evaluation criteria.
As a result of the examination until 2009, in accordancewith the
Pharmaceutical Affairs Law, and with the goal of facilitating clinical
application of the products derived from human somatic stem cells,
iPS cells, ES cells, and other relevant cells, the study group
concluded that to facilitate the conduct of efﬁcient, effective, and
rational research and development (R&D), the relevant guidelines
should be tailored to speciﬁc cell sources and phenotypes (autol-
ogous human versus allogeneic human, and somatic stem cells vs.
iPS cells vs. ES cells vs. other cells). Points to be considered include
but are not limited to relevant technical details, the manufacturing
process, characterization, quality control, and stability evaluation as
well as the data required to determine the safety and efﬁcacy of the
products.
In 2009, 2 interim reports on draft guidelines on autologous
human somatic stem cell-based products and autologous human
iPS(-like) cell-based products were developed based on the
existing Japanese Ministry of Health, Labour and Welfare Notiﬁ-
cation No. 0208003 and on the above considerations. Three other
interim reports detailing draft guidelines were also developed for
allogeneic human somatic stem cell-based products, allogeneic
human iPS(-like) cell-based products and human ES cell-based
products according to Japanese Ministry of Health, Labour and
Welfare Notiﬁcation No. 0912006. These 5 sets of draft guidelines,
still at the interim stage, were presented as the subjects of thor-
ough discussions from a variety of viewpoints. They were widely
circulated among the interested parties as articles published in a
relevant scientiﬁc journal to elicit readers' comments (Hayakawa
T., et al.: Regenerative Medicine [Journal of the Japanese Societyfor Regenerative Medicine], 9, 116e180 [2010], in Japanese).
Thereafter, these articles were updated and published as a series
of 8 articles (Journal of the Japanese Society for Regenerative
Medicine, 10, 86e152 [2011], in Japanese), which would form the
basis of the ﬁnal draft guidelines. After extensive discussions with
the study group and after public consultation, the Pharmaceutical
and Food Safety Bureau of the Ministry of Health, Labour and
Welfare of Japan issued 5 notiﬁcations on September 7, 2012, as
described previously [1].
In this paper, in continuation of the previous papers [1e3], we
introduce guidelines on the basic technological requirements for
ensuring the quality and safety of pharmaceuticals and medical
devices derived from the processing of allogeneic human iPS(-like)
cells.
The generation of iPS cells by Yamanaka and colleagues
demonstrated that differentiated cells can be reprogrammed arti-
ﬁcially. This monumental work suggests that differentiation and
dedifferentiation can be manipulated as needed. The technology
raises great hopes of practical application in basic biological
research, medical research on pathogenesis, drug discovery
through establishment of novel systems for efﬁcacy and toxicity
tests, and in regenerative medicine.
Needless to say, the ultimate goal of regenerative medicine is
to treat patients. Therefore, we should always adopt a treatment
(objective)-oriented approach and give priority to the consider-
ation of potential target diseases and products for development.
The paradigm shift brought by the discovery of iPS cells provides
limitless possibilities for regenerative medicine. This, however,
does not necessarily mean that all regenerative medicine should
be practiced on the presupposition of a standardized degree of
reprogramming or other properties of iPS cells. If iPS cells can be
standardized and their state of pluripotency made precisely con-
stant, iPS cells may serve as crucial and highly speciﬁc raw ma-
terials for the development of cell-based pharmaceuticals and
medical devices for regenerative medicine. However, this does not
necessarily mean that all products shall be produced using a
speciﬁc iPS cell lineage. It is crucial to consider that when
manufacturing an individual product from a certain type of cells,
the cells chosen should be the “appropriate raw materials” for the
product. In other words, the most important criterion for certain
artiﬁcially induced pluripotent stem cells would be whether they
have been conﬁrmed to be a suitable raw material for the
manufacture of a ﬁnal product; this approach ensures quality,
efﬁcacy, and safety sufﬁcient for a speciﬁc treatment (objective).
The challenges for the researchers and developers would include
(1) which types of pluripotent stem cells to use as a raw material:
cell-of-origin, reprogramming method, and degree of reprogram-
ming; and (2) how to obtain the ﬁnal product from the pluripo-
tent stem cells: the differentiation protocol and intermediate cell
state.
Based on the concept mentioned above, these guidelines refer to
both “human iPS cells” and “human iPS-like cells” and provisionally
deﬁne these 2 types of cells as follows:
“Human induced pluripotent stem cells (iPS cells)”: Cells
generated from somatic cells through artiﬁcial reprogramming by
introducing genes or proteins, or, for instance, by chemical or drug
treatment, or cells that are obtained from such cells through cell
division, and which possess the ability to differentiate into the
endoderm, mesoderm, and ectoderm, and furthermore, maintain
the ability to self-renew or a similar ability.
“Human induced pluripotent stem-like cells (iPS-like cells)”:
Cells generated from somatic cells through artiﬁcial dedifferentia-
tion by introducing genes or proteins, or, for instance, by chemical
or drug treatment, or cells that are obtained from such cells through
cell division, and which at least possess the ability to differentiate
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furthermore, to maintain the ability to self-renew or a similar
ability.
Raw materials in biologics cannot be adequately characterized
or quality controlled due to their indistinct origin and
complexity; the same holds true for ﬁnal products due to their
limited quantity and complex quality attributes. To address these
concerns, it is very important to ensure constancy and robustness
of the manufacturing process in the production of all types of
biologics. The core technical elements required is to establish
base camp(s), i.e., to prepare substrates for production of bi-
ologics at relevant stage(s) in the manufacturing process; these
substrates can be extensively characterized and controlled and
are of stable quality, and constant processing of these substrates
into the subsequent intermediate(s) and ﬁnally to a desired
product is achievable.
The ideal base camp(s) in the sustainable manufacture of
human iPS or iPS-like cell-based products are cells (banks) and/
or intermediate cell products/lines that have been well charac-
terized, are stable per se but can propagate under appropriate
conditions, can be renewed, are ready for supply upon request,
and can differentiate into target cells. For certain ﬁnal products,
it may be more feasible for the consistent, safe manufacture of
the desired products to establish sustainable intermediate cell
products/lines (as a form of a cell bank) at an intermediate stage
of the manufacturing process than to emphasize characteriza-
tion, evaluation, or control of cells at the raw-material stage,
which may be difﬁcult to perform. It is, of course, essential to
explain the advantages and appropriateness of such a procedure.
When establishing cell lines at each stage of differentiation with
different phenotypes, the procedures for the process of cell
generation such as differentiation, isolation, and cultivation of
target cells; generation of cell lines; the growth medium; culture
conditions; culture period; and survival rate should be clearly
documented and justiﬁed as much as possible. To maintain the
consistency and stability of intermediate cell products/lines,
critical indicators such as purity, morphology, speciﬁc cell
markers, karyotypes, proliferation, and differentiation, should be
selected and acceptance criteria should be set accordingly. In
addition, the passage number and/or population doublings of
intermediate cell products/lines should be speciﬁed so that
quality meets the acceptance criteria.
For products derived from human iPS cells or iPS-like cells
(hereafter referred to as iPS(-like) cells), the presence of undif-
ferentiated cells in ﬁnal products is a major safety concern (e.g.,
ectopic tissue formation and tumorigenesis). However, because
this concern is raised from one of iPS(-like) cells' strongest
characteristics, it is quite difﬁcult to avoid. Elimination of
intrinsic characteristics of iPS(-like) cells is a trade-off at least in
principle, and is thus considered very difﬁcult. Accordingly, it is
necessary to have a strategy and tactics to develop safer ﬁnal
products by improving the manufacturing process and process
control more effectively rather than discussing safety issues at
the iPS(-like) cell level. These draft guidelines, therefore, require
demonstration of the absence of undifferentiated cell contami-
nation at the level of an iPS(-like) cell-derived bank and/or in-
termediate and/or ﬁnal cell products thorough analysis or an
effort to develop efﬁcient methods to eliminate or inactivate
undifferentiated cells in the course of cell processing. Further-
more, selection of administration methods will help to minimize
safety concerns. These guidelines also explain the importance of
technical development to generate and characterize iPS(-like)
cell-derived somatic stem cells, which may lead to safe, stable,
characteristically well-deﬁned and appropriate raw materials. In
addition, the need for R&D on examination techniques to predictthe pluripotency and differentiation potential of each iPS(-like)
cell lineage and processing techniques to induce target cells
efﬁciently and properly and to isolate differentiated cells from
undifferentiated cells during processing will provide novel busi-
ness opportunities.
These draft guidelines include discussion of all of the above-
stated aspects of iPS(-like) cells. The iPS(-like) cells possess
pluripotency and self-replication abilities exceeding those of
normal somatic stem cells and can therefore differentiate into a
variety of cell types depending on the processing techniques
used. Such iPS(-like) cell-based products will be clinically applied
heterologously, i.e., in an environment that differs from the
environment where the cells perform their natural endogenous
function. Concerns about these points have been included in
these human iPS(-like) cell guidelines in reference to Japanese
Ministry of Health, Labour and Welfare Notiﬁcations No.
0208003 and No. 0912006.
When interpreting and implementing the present guidelines,
the following arguments should be considered. The ultimate goal is
to provide novel therapies to patients by means of regenerative
medicine. The role of these guidelines is to present scientiﬁc
principles, concepts, ideas, and technical elements that should help
to achieve a speciﬁed goal in the most efﬁcient and effective
manner possible. Because a wide variety of products are antici-
pated, encompassing a variety of situations and circumstances,
these guidelines describe comprehensive points of concern. It is
necessary to determine the relevant testing parameters and eval-
uation methods by considering the characteristics of the cells in
question, the speciﬁc clinical objective, and the method of appli-
cation (among other factors). Those items that are applicable
should be justiﬁed and put into practice in an appropriate and
ﬂexible manner.
Several points should be kept in mind with regard to the
development of products for regenerative medicine and the
implementation of this guideline. The desired products are ex-
pected to show promise as a novel therapeutic method as a result of
proof of concept (POC) and relevant data indicating no critical
concerns about product safety that might impede the use of the
products in humans. Thorough observance of the Declaration of
Helsinki, including proper informed consent and the right of self-
determination of the patient, is indispensable.
It should be emphasized again that our primary goal is to
offer suitable medical opportunities as soon as possible to pa-
tients with severe diseases that are difﬁcult to treat with con-
ventional modalities. The present guideline should serve this
purpose. Therefore, it is important to interpret and employ
these guidelines ﬂexibly and meaningfully in this context.
Stringent observance of these guidelines without primary
consideration of the patient and his/her speciﬁc situation should
be avoided.
Progress in the actual use of regenerative medicine is clearly
desirable for maintaining and improving human health. The
development of innovative and revolutionary medicinal products
and therapeutic techniques should be beneﬁcial to our country as
well as the international community and is a way to make a
peaceful international contribution that will be a legacy for all
mankind. The role of the government here is to promote clinical
research and industrialization; relevant regulations and guide-
lines are important measures undertaken to achieve this com-
mon goal in a scientiﬁc, rational, efﬁcient, and effective way. All
those involved, like players in the same arena with a common
goal in mind, accumulating scientiﬁc data and concentrating
wisdom, should continue to make efforts to deliver these revo-
lutionary cell-based products and therapeutic techniques to pa-
tients as soon as possible.
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(Notiﬁcation No. 0907-5, issued by Pharmaceuticals and Food
Safety Bureau, Ministry of Health, Labour and Welfare of Japan, on
September 7, 2012).
2. Introduction
1. The present guidelines outline the basic technical elements for
ensuring the quality and safety of pharmaceuticals and medical
devices derived from the processing of allogeneic human
induced pluripotent stem (iPS) cells or allogeneic human iPS-
like cells (excluding autologous human iPS cells and autolo-
gous human iPS-like cells). These products are hereafter
referred to as allogeneic human iPS(-like) cell-based products or
simply as “desired cell products.”
Allogeneic human iPS(-like) cell-based products are obtained by
artiﬁcially inducing the differentiation of various types of iPS(-
like) cells generated artiﬁcially from allogeneic human somatic
cells; they are used directly or after further processing. There are
many types of manufacturing methods, intermediates, types,
and characteristics of the desired cell products, and methods for
clinical application. In addition, the scientiﬁc progress in this
ﬁeld is incessant, while expertise and knowledge are constantly
accumulating. Therefore, it is not always appropriate to consider
the present guidelines all-inclusive and deﬁnitive. Conse-
quently, when testing and evaluating each product, it is neces-
sary to adopt, on a case-by-case basis, a ﬂexible approach in
accordance with a rationale that reﬂects scientiﬁc and techno-
logical advances at that point in time.
2. The main purpose of evaluating the quality and safety of the
desired cell products before conducting investigational clinical
trials (e.g., at the time of “clinical-trial consultation”) is to
determinewhether there are any quality and/or safety problems
that would obviously hinder initiation of human clinical trials of
the iPS(-like) cell-based products in question, whether certain
quality attributes (QA) of the product are understood sufﬁ-
ciently to establish the relationship between clinical ﬁndings
and the QA, and whether consistency of the QA can be ensured
within a deﬁnite range. Simultaneously, it is important to
eliminate any known risk factors associated with the product
quality and safety as much as possible using up-to-date science
and technology, and to describe the scientiﬁc appropriateness of
the results of such an action. The remaining presumed risk
factors should be weighed against the risks associated with not
performing the trials on patients who suffer from diseases that
are serious and life-threatening or that involve marked func-
tional impairment, or a marked decrease in quality of life (QOL)
resulting from the loss of a certain degree of physical function or
form, or for which existing therapies have limitations and do not
result in a cure. Furthermore, it is also important to entrust the
patient with the right to make a decision after receiving all of
the available information. When applying for approval of
investigational clinical trials, applicants can submit a reasonably
prepared provisional nonclinical data package, which is pre-
pared rationally by taking into account product aspects and
patient aspects including a balance between the risk of the
product vs. the risk facing the patient with/without treatment in
question, for the decision to initiate investigational clinical tri-
als, on the premise that the data package for ensuring quality
and safety at the time of marketing application/registration will
be enriched in line with the guidelines as the clinical trial
progress.Finally, applicants are encouraged to discuss with the Pharma-
ceuticals and Medical Devices Agency (PMDA) the type and
extent of data that may be needed to initiate a particular clinical
trial. Because of differences in product origin, target disease,
target patients, application sites, application methods, and
processing methods, there may be numerous variations among
individual data packages; these differences cannot be deﬁni-
tively clariﬁed in the present guidelines.
3. The items, test methods, criteria, and any other technical re-
quirements described in the present guidelines are intended to
be considered, selected, applied, and evaluated to serve each
intended purpose; they do not necessarily require the most
stringent level of interpretation and practice. Applicants are
encouraged to explain and provide justiﬁcation for any consid-
erations of regarding the background, selection, application, and
the content and extent of evaluation that are appropriate for
their own purpose and are scientiﬁcally valid.3. Chapter I. General principles
3.1. Objective
The present guidelines outline the basic technical elements for
ensuring the quality and safety of pharmaceuticals and medical
devices derived from the processing of allogeneic human induced
pluripotent stem (iPS) cells or allogeneic iPS-like cells (excluding
autologous human iPS cells and autologous iPS-like cells). These
products are hereafter referred to as allogeneic human iPS(-like)
cell-based products or simply as the “desired cell products.”
3.2. Deﬁnitions
The deﬁnitions of the technical terms used in these guidelines
are as follows:
1. “Human induced pluripotent stem cells (iPS cells)”: Cells that
are generated from somatic cells through artiﬁcial reprog-
ramming by introducing genes or proteins, or via chemical or
drug treatment, or cells that are obtained from such cells
through cell division, and which possess the ability to differ-
entiate into the endoderm, mesoderm, and ectoderm, and
furthermore, to maintain the ability to self-renew or a similar
ability.
2. “Human induced pluripotent stem-like cells (iPS-like cells)”:
Cells that are generated from somatic cells through artiﬁcial
dedifferentiation by introducing genes or proteins, or via
chemical or drug treatment, or cells that are obtained from such
cells through cell division, and which at least possess the ability
to differentiate into some type of endoderm, mesoderm, or
ectoderm, and furthermore maintain the ability to self-renew or
a similar ability.
3. “Processing of cells and tissues”: Any processing of a cell type or
tissue, such as propagation and/or differentiation, production of
a cell line, activation of a cell by pharmaceutical or chemical
treatment, alteration of a biological characteristic, combination
with a noncellular component, or manipulation using genetic
engineering, with the aim of preparing desired cell products to
treat a patient or to repair or regenerate tissues.
Isolation of a tissue, homogenization of a tissue, separation of
cells, isolation of a speciﬁc cell, treatment with antibiotics,
washing, sterilization by g-irradiation or other methods,
freezing, thawing, and other such procedures that are regarded
as minimal manipulations are not considered “processing.”
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allogeneic human iPS(-like) cell-based product) is released to
the market. This includes, in addition to processing of cells and
tissues, minimal manipulations such as isolation of a tissue,
homogenization of a tissue, separation of cells, isolation of a
speciﬁc cell, treatment with antibiotics, washing, sterilization by
g-irradiation or other methods, freezing, thawing, and other
procedures that do not change the original properties of the
cells or tissues.
5. “Phenotype”: A morphological or physiological characteristic
that is produced by a certain gene under constant environ-
mental conditions.
6. “HLA typing”: Identiﬁcation of the type of HLA (human leuko-
cyte antigen), a human primary histocompatibility antigen.
7. “Donor”: A person who donates his/her own somatic cells,
which serve as the raw material for an allogeneic human iPS(-
like) cell-based product.
8. “Transgenic construct”: A construct that contains a vector for
introducing a target gene (a speciﬁc gene encoding a desired
protein or RNA) into a target cell, the target gene itself, and the
coding sequences of the elements essential for the expression of
the target gene.
9. “Protein transductant”: A construct that contains a target pro-
tein and elements such as reagents necessary for introducing
the target protein into a target cell.
4. Chapter II. Manufacturing method
Describe all the important and relevant information concerning
the manufacturing method, taking into account the items listed
below. This information will contribute to ensuring the quality,
safety, and efﬁcacy of the ﬁnal products and is important for
guaranteeing quality consistency from the manufacturing
perspective. It should be noted that assurance of quality and safety
and their consistency is achieved via mutual complementary
measures throughout the manufacturing method as a whole, and it
is very important that the measures be rational and serve the
intended purpose. It is acceptable to omit a portion of the items
listed below if the appropriate scientiﬁc basis for ensuring the
quality, safety, and constancy of the ﬁnal products can be provided
by means of suitably chosen quality tests or controls of the ﬁnal
products or intermediates, or control of the manufacturing process.
4.1. Raw materials and materials used in manufacturing
4.1.1. Human somatic cells that serve as raw materials
(1) Source and origin, justiﬁcation of their selection
Explain the source and origin of the somatic cells used as raw
materials when establishing the human iPS(-like) cell line and
provide the reasons for selecting these somatic cells.
(2) Characteristics and eligibility of somatic cells serving as raw
materials
(i) Features of biological structure and function, selection
criteriaProvide and explain the reasons for selecting the somatic cells
used as raw materials with reference to characteristics of their
biological structure and function, such as morphological charac-
teristics, growth characteristics, biochemical indicators, immuno-
logical indicators, speciﬁc substances produced, results of HLA
typing, and other suitably chosen and appropriate genotype or
phenotype indicators.This should lead to the identiﬁcation of the critical cell charac-
teristics that are to be employed when preparing the somatic cells
as raw materials. It is recognized that quantitative or technological
limits on sample analysis will affect the extent to which such
studies can be performed.
(ii) Donor selection criteria and eligibility
Indicate that the donor was selected in an appropriate and
ethical manner and that the proper procedure was followed.
Establish selection criteria and eligibility criteria that take into
consideration age, sex, ethnic characteristics, genetic characteris-
tics, the medical history, the health condition, test parameters
related to any type of infection thatmay be transmitted via cell and/
or tissue samples, immunological compatibility, and other charac-
teristics and explain their appropriateness. If donor genomic or
gene analysis is undertaken, it shall be performed in accordance
with “Ethical Guidelines for Analytical Research on Human
Genome/Gene,” issued jointly on February 8, 2013, and revised on
November 25, 2014, by the Japanese Ministry of Education, Culture,
Sports, Science and Technology; Ministry of Health, Labour and
Welfare; and Ministry of Economy, Trade and Industry.
Infections with hepatitis B virus (HBV), hepatitis C virus (HCV),
human immunodeﬁciency virus (HIV), adult human T-lymphotropic
virus (HTLV), orparvovirusB19 shall be ruledout viaphysician-donor
interviews and clinical laboratory tests, such as serological tests and
nucleic-acid ampliﬁcation tests. Infection with cytomegalovirus,
Epstein-Barr (EB) virus, or West Nile virus shall also be ruled out, if
necessary, by performing the appropriate clinical laboratory tests.
In addition, further assess and determine the eligibility of do-
nors by examining the medical history (mentioned below) of the
donor, for example, through physician-donor interviews, and
determine whether he/she ever received a blood transfusion or
underwent a transplant procedure.
 Bacterial infections, such as syphilis (Treponema pallidum),
chlamydia, gonorrhea, and tubercle bacillus
 Sepsis or suspected sepsis
 A malignant neoplasm
 Serious metabolic or endocrine diseases
 Collagen and blood diseases
 Hepatic diseases
 Conﬁrmed or suspected transmissible spongiform encephalop-
athy (TSE) or other brain disorders
 A speciﬁc genetic disease or a family history of a speciﬁc genetic
disease
Alternatively, it is acceptable to perform some parts of the
aforementioned studies concerning speciﬁc genetic features or
infection status of the donors at the stage of cells (intermediate
products or cell banks) derived from iPS(-like) cells in lab tests,
after having demonstrated their appropriateness.
(3) Records related to the donor
Retain complete records related to the donors so that any in-
formation necessary to ensure the safety of somatic cells that are
used as raw materials can be veriﬁed. Concrete measures shall be
described. For patients and donors of test samples, it is sufﬁcient to
prepare and retain only speciﬁc information that is related to the
intended use of the cells.
(4) Collection, storage, and transport of cells and tissues
(i) Eligibility of personnel andmedical institutions collecting
the samples
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institutions that collect the cells and tissues.
(ii) Suitability of the sampling site and sampling method
Describe the rationale for selecting the cell and tissue sampling
sites and the sampling method. State why the selected sites are
scientiﬁcally and ethically appropriate. For cell and tissue sampling
methods, indicate the suitability of the equipment and drugs used
and the measures adopted to prevent microbial contamination,
erroneous sampling (mix-up), and cross-contamination.
(iii) Informed consent of donors
Describe the details of the informed consent, including the
clinical application, provided by the donor of the cells or tissue.
(iv) Protection of donor privacy
Indicate the measures adopted to ensure the protection of the
donors' privacy.
(v) Tests to ensure donor safety
If tests such as those to conﬁrm the state of the sampling site
need to be performed in order to ensure the safety of the donor at
the time of cell or tissue sampling, describe the details of the tests
as well as any interventions undertaken after test results indicate a
problem.
(vi) A storage method and measures to prevent erroneous sam-
pling (mix-up)
If the somatic cells that are collected must be stored for a
deﬁned period of time, set the storage conditions and storage
duration and explain their appropriateness (validity). Describe in
detail the measures and procedures to be followed to prevent
erroneous sampling (mix-up).
(vii) Transportation methods
If cells and/or tissues or iPS(-like) cells that were collected must
be transported, deﬁne the containers to be used for transport and
the transportation procedure (including temperature control) and
provide the justiﬁcation.
(viii) Preparation of records and storage procedures
Written records for items (i) through (vii) above shall be pre-
pared, and proper record storage procedures shall be described in
detail.
4.1.2. Raw materials other than target cells and tissues as well as
materials used in manufacturing
Describe any raw materials other than the target cells and tis-
sues as well as other materials used in the manufacturing process
and indicate their appropriateness for their intended use; if
necessary, establish their speciﬁcations (a set of acceptance criteria
and analytical procedures). Proper quality control of these mate-
rials should be implemented.
When so-called Biological Products or Speciﬁc Biological Prod-
ucts (refer to Articles 2.9 and 2.10 of the Pharmaceutical Affairs
Law) are used as rawmaterials, the amounts used should be kept to
the minimum amount required and should strictly conform to the
relevant laws and regulations, such as the “Standards for BiologicalRaw Materials” (Notiﬁcation No. 210, Japanese Ministry of Health,
Labour andWelfare, 2003; a partially revised versionwas issued on
September 26, 2014). It is particularly important to adequately
evaluate the information related to inactivation and elimination of
viruses and to indicate measures for encouraging retrospective
survey and other studies.
The technical requirements described in this paragraph should
be taken into considerationwhen the process of reprogramming or
dedifferentiation from the raw materials into iPS(-like) cells or of
directed differentiation from iPS(-like) cells into the ﬁnal products
in question include any relevant elements/concerns.
(1) Cell Culture
(i) Indicate the appropriateness of all components of any
media including such as additives (e.g., serum, growth
factors, and antibiotics), and reagents used for the
treatment of cells and set speciﬁcations if necessary.
Consider the route of clinical application and other
parameters of the ﬁnal product when setting speciﬁ-
cations concerning the appropriateness of each
component.
(ii) Consider the following points with respect to media
components
(a) The ingredients and water used in media should be
of high quality and high biological purity; quality
should be controlled using standards equivalent to
those for pharmaceuticals and pharmaceutical
ingredients.
(b) Provide information on not only the main in-
gredients used in the media but all components as
well as the rationale for their selection and if
necessary the quality control and other procedures.
However, widely known and commercially avail-
able media products such as DMEM, MCDB, HAM,
and RPMI are regarded as a single raw-material set.
(c) Conduct sterility and performance tests on media
that contain all components to determine their
suitability as target media. Set speciﬁcations for
any other relevant parameters thought to be
controlled in the manufacturing process and
perform proper quality control.(iii) Heterologous serum or components derived from
heterologous or homologous serum shall not be used
unless they are essential for processes such as cell
activation or cell growth. In particular, for products that
may be used repeatedly, investigate, to the extent
possible, ways to avoid using these serum components.
If the use of serum or other such material is unavoid-
able, consider the following points, and investigate
ways to prevent the contamination and spread of
bacteria, fungi, viruses, and prions from the serum and
other related materials as well as treatment methods
for their elimination, to the extent possible, from the
ﬁnal product.
(a) Clarify the origin of the serum or other
components.
(b) Make strenuous efforts to minimize the risk of
prion infection, for example by strictly avoiding the
use of serum from areas or regions with known
outbreaks of bovine spongiform encephalopathy
(BSE).
(c) Use these batches of serum only after having con-
ﬁrming that they are not contaminated with vi-
ruses or other pathogens by conducting
appropriate tests to prove the absence of speciﬁc
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(d) Conduct appropriate inactivation and elimination
procedures for bacteria, fungi, and viruses to an
extent that does not impact the activation and
growth of the cells. For example, to avoid the risks
associated with latent viral contamination, use
combinations of heat treatment, ﬁltration, g-irra-
diation, and/or ultraviolet light treatment, if
necessary.
(e) Preserve and store a portion of the serum to enable
monitoring of cultured cells for viral infections and
onset of viral diseases among the patients and
measure antigen production in response to a
component of the heterologous serum used.(iv) When using feeder cells, conduct quality evaluation
while referring to “Derivation and Characterization of
Cell Substrates Used for Production of Biotechnological/
Biological Products” (Pharmaceutical Notiﬁcation No.
873, July issued 14, 2000, Evaluation and Licensing Di-
vision, Pharmaceutical and Food Safety Bureau, Japa-
nese Ministry of Health, Labour and Welfare),
“Guidelines on Public Health Infection Issues Accom-
panying Xenotransplantations” (Notiﬁcation No.
0709001, issued July 9, 2002, Research and Develop-
ment Division, Health Policy Bureau, Japanese Ministry
of Health, Labour and Welfare), and “Guidelines on
Epithelial Regenerative Therapy Using 3T3J2 Strain or
3T3NIH Strain Cells as Feeder Cells” based on “Guide-
lines on Public Health Infection Issues Accompanying
Xenotransplantations” (Notiﬁcation No. 0702001, is-
sued July 2, 2004, Research and Development Division,
Health Policy Bureau, Japanese Ministry of Health, La-
bour and Welfare) in order to prevent contamination
and transmission of bacteria, fungi, viruses, and prions
from the feeder cells; indicate the methods used for
inactivation of the cell division potential and conditions
such as cell density. However, for example, if the feeder
cells or equivalent cells are being used in the manu-
facture of a cell or tissue product that has previously
been used clinically and whose characteristics and
microbiological safety have already been assessed and
conﬁrmed, it is possible to omit the virus tests or por-
tions of other tests by demonstrating the eligibility of
these cells.
(v) The use of antibiotics should be avoided as much as
possible. However, if antibiotics are deemed indis-
pensable at the initial stages of processing, attempt to
decrease their use at subsequent steps as much as
possible and clearly state the appropriateness of their
use, including the scientiﬁc rationale, estimated resid-
ual amounts in the ﬁnal product, and effects on the
patient. If it has been determined that an antibiotic can
be adequately eliminated from the ﬁnal product, its use
does not need to be restricted. However, if a patient has
a history of allergy to the antibiotic used, this thera-
peutic method should not be prescribed. If the use of
antibiotics cannot be avoided, administer them care-
fully and ensure that informed consent is obtained
from the patient.
(vi) If growth factors are used, demonstrate the appropriate
quality control methods using relevant parameters, for
example purity and potency, for which established
acceptance criteria and assay methods are employed,such as purity and potency, to guarantee the repro-
ducibility of cell culture characteristics.
(vii) For media components and other components used in
processing and those that may contaminate the ﬁnal
product, choose components with no harmful biolog-
ical effects.
(viii) When using cells derived from a different species
(heterologous cells) as feeder cells, ensure that there is
no risk of infection from the cells of heterologous origin.(2) Combination of cells with noncellular components
(i) Quality and safety of noncellular raw materialsIf the ﬁnal product consists of cells combined with noncellular
components such as a matrix, medical materials, scaffolds, support
membranes, ﬁbers, or beads, describe in detail the quality and
safety of the noncellular components.
Provide any relevant information concerning the noncellular
raw materials, taking into consideration their type and charac-
teristics; the form and function in the ﬁnal product; and evalua-
tion of their quality, safety, and efﬁcacy or the presumed clinical
indication. When using materials that are absorbed by the body,
perform the necessary tests for the safety of any degradation
products.
To determine which tests are required, refer to “Basic Views on
Biological Tests Necessary for Regulatory Approval for Manufac-
tured or Imported Medical Devices” (Notiﬁcation No. 02013001,
issued February 13, 2003, Pharmaceutical and Food Safety Bureau,
Japanese Ministry of Health, Labour and Welfare), describe the test
results, and provide justiﬁcation for the use of such raw materials.
Rational use of information from scientiﬁc literature is also
encouraged.
(ii) Interactions with target cells
Demonstrate the validity of the tests methods used and provide
justiﬁcation for the results obtained for the following 3 items with
respect to the interactions between noncellular components and
cells in the ﬁnal product and in any intermediate products.
(a) The noncellular components do not have any deleterious
effects on the function, growth capacity, activity, or stability
of the cells in the ﬁnal product required for the presumed
clinical indication or the cells in any intermediate products.
(b) Evaluate to the extent possible any potential interactions
between the cells and noncellular components, taking into
consideration, for example, mutation, transformation, and/or
dedifferentiation of the cells in the ﬁnal or intermediate
products.
(c) Demonstrate that there is no loss of the expected properties
of the noncellular components for the presumed clinical
indication due to any interactions between the noncellular
components and the cells in the ﬁnal and intermediate
products.
(iii) Use of noncellular components to isolate the desired cell
products from the application site.
When using noncellular components with the objective of
segregating the cells from the application site, conﬁrm their use-
fulness and safety by referring to points (a) through (e) below.
(a) When immunological segregation is the objective, describe
its level.
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fects of target physiologically active substances derived from
the cells in the ﬁnal product.
(c) Diffusion of nutritional components and excretory products.
(d) Effects of noncellular components on the area near the
application site.
(e) When a pharmacological effect of a target physiologically
active substance that was derived from a desired cell product
is anticipated and segregation of the application site and the
desired cell products and/or undifferentiated cells is the
objective, conﬁrm that the cells will not leak due to, for
example, degradation of the noncellular components.
(3) Genetic modiﬁcation of cells
When genes are introduced into the cells, provide details on the
following items.
(i) For the target gene (the speciﬁc gene encoding a desired
protein or RNA): information related to its structure, origin,
method by which it was obtained, cloning methods; for the
cell bank of the target gene: methods of preparation, control,
and renewal, and other relevant information.
(ii) Nature of the transgene.
(iii) Structure, biological activity, and properties of the desired
proteins or RNA derived from the target gene.
(iv) All the raw materials, their properties, and procedures
(transgenic method, and origin, properties, and method for
obtaining the vector used for introduction of the transgene)
required to produce the transgenic construct.
(v) Structure and characteristics of the transgenic construct.
(vi) Control and preparation methods for cell and virus banks
that are used to prepare vectors and transgenic constructs.
For manufacturing methods for transgenic cells, refer to Chapter
2 and other sections of the “Guidelines for Ensuring the Quality and
Safety of Gene Therapy Pharmaceuticals,” which is an appendix of
“Concerning Guidelines for Ensuring the Quality and Safety of Gene
Therapy Pharmaceuticals” (hereafter referred to as “Gene Therapy
Pharmaceutical Guidelines”), published as Notiﬁcation No. 1062 by
Pharmaceutical Affairs Bureau, Japanese Ministry of Health and
Welfare on November 15, 1995. In addition, clearly state the
appropriateness of the establishment of a cell line in accordance
with the appendix of the same notiﬁcation.
Be aware that, based on the law (Law No. 97, 2003) for ensuring
the biodiversity by regulating the use (and other aspects) of
genetically modiﬁed organisms and related organisms, a separate
application procedure for evaluation will be required when living
organisms, including certain cells, “viruses,” and “viroids,” are
genetically modiﬁed. The following cells are not regarded as a living
organism: “human cells” or “cells that have the ability to differ-
entiate, or differentiated cells that are not viable when alone under
natural conditions.”
Regardless of the above, if a gene that was introduced into cells
is used as a reagent in the manufacturing process but is neither
chemically nor functionally present in the ﬁnal product, it is
acceptable to simply describe how the quality and safety of the
gene conform to the intended use, based on the most current
knowledge.
(4) Introduction of proteins into cells
When proteins are introduced into cells, provide the details on
the items listed below.(i) Origin and quality attributes including protein structure,
biological activity, and physicochemical properties.
(ii) Information concerning the procurement, manufacturing,
quality control, and renewal methods for the proteins.
(iii) Methods for introducing the proteins into the cells.
(iv) Quality attributes including the structure, biological activity,
and physicochemical properties of the chemical substances
used to introduce the proteins into the cells.
(v) When preparing a construct for introducing the proteins in
question into cells, provide information on its preparation,
quality control, and renewal methods.
(vi) Preparation of cell banks and cell bank control methods to
produce the introduced proteins.
Regardless of the above, if a protein that is introduced into cells
is used as a reagent in the manufacturing process but is neither
chemically nor functionally present in the ﬁnal product, it is
acceptable to simply describe how the quality and safety of the
protein corresponds to the intended use.
(5) Reprogramming, or inducing dedifferentiation and/or dif-
ferentiation of cells using drugs or any other chemicals
When inducing reprogramming or dedifferentiation and/or
differentiation of cells using drugs or any other chemicals, provide
the details on the following items.
(i) Origin and quality attributes including structure, biological
activity (if any), and physicochemical properties of the drugs
or chemicals in question.
(ii) Information concerning the procurement, manufacturing,
quality control, and renewal methods for the target drugs or
chemicals.
(iii) Cell treatment methods using, for example, target drugs.
(6) Cell reprogramming, dedifferentiation, and/or differentiation
using physical methods
Describe the details of the methods used when inducing cell
reprogramming or induction of dedifferentiation and/or differen-
tiation using physical methods in question.
(7) Cell reprogramming, dedifferentiation, and/or differentiation
using a combination of methods
Describe the details of the methods when using any combina-
tion of genetic modiﬁcation, introduction of a protein, drug/
chemical treatment, or physical methods to induce cell reprog-
ramming, dedifferentiation, and/or differentiation.
4.1.3. Establishment of allogeneic human iPS(-like) cell lines
Establish allogeneic human iPS(-like) cell lines after having
determined as thoroughly as possible the genetic background of the
donor. Describe the methods used up until the establishment of
iPS(-like) cell lines from the somatic cells that serve as the raw
material and describe, as thoroughly as possible, the appropriate-
ness of the methods. These include the methods for obtaining the
human somatic cells, for separating and culturing of somatic cells,
for inducing reprogramming or induction of dedifferentiation of
the somatic cells, for isolating and preparing cell lines of the
reprogrammed or dedifferentiated cells as well as the media, cul-
ture conditions, culture period, yield, and other parameters at each
step in the process until establishment of the allogeneic human
iPS(-like) cell line.
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the human iPS(-like) cell lines, identify critical quality attributes of
the cells (for example, cell population purity, morphological fea-
tures, HLA typing, phenotype-speciﬁc markers, karyotype, DNA
ﬁngerprinting, cell growth properties, and pluripotency) and set
acceptance criteria for them. In addition, demonstrate the number
of passages or of cell divisions within which cells can proliferate
while maintaining their quality in terms of the criteria speciﬁed.
4.1.4. Storage and transport of human iPS(-like) cell lines
For human iPS(-like) cell lines, perform appropriate stability
tests based on the viability, potency, and other characteristics of the
cells, establish the storage method and validity period, and clarify
their suitability, considering storage duration, distribution, and the
storage form. In particular, when freezing and thawing, conﬁrm
whether freezing and thawing affect the stability or any other
characteristic of the cell line. Where necessary and possible,
conduct stability studies on the cell line whose storage period ex-
ceeds normal periods in order to conﬁrm, to the extent possible, the
limits of stability. However, this does not apply if the cells will be
used immediately after being established.
When transporting human iPS(-like) cells, the containers used
for transport and the transportation procedures (including tem-
perature control) shall be determined and their appropriateness
clearly indicated.
4.1.5. Preparation of records and storage procedures
Written records for 4.1.2e4.1.4 items above shall be prepared
and proper record storage procedures shall be clearly described.
4.2. Manufacturing process
When manufacturing allogeneic human iPS(-like) cell-based
products, describe in detail the manufacturing method and verify,
as thoroughly as possible, the appropriateness of the method using
the items listed below to maintain consistent product quality.
4.2.1. Lot control
Indicate whether a lot control procedure is applied for ﬁnal and
intermediate products. If any lot control is adopted, establish
standardized procedures for the makeup and control of the lot,
which may include the lot size, labeling/numbering, testing
method and acceptance criteria.
4.2.2. Manufacturing method
Provide an outline of the manufacturing method from the time
of receipt of the cells and tissues or somatic cells (that serve as the
raw materials) to the establishment of allogeneic human iPS(-like)
cells and cells that have progressed to the differentiation stage and
then to the ﬁnal product. Describe the technical details of the
process and the required process and product quality control.
(1) Tests upon receipt
Establish a battery of tests and acceptance criteria to assess
appropriateness of the cells and tissues, somatic cells or allogeneic
human iPS(-like) cells that will serve as the raw materials, taking
into account the nature of the cells and their intended use. These
may include, for example, visual tests, microscopic examination,
recovery factors of target cells, cell viability, characterization of
cells and tissues, and microbiological tests. At the stage of initiation
of clinical trials, provide the actual measured values obtained using
test samples, and propose a provisional set of acceptance criteria
based on these values.(2) Inactivation and elimination of bacteria, fungi, viruses, and
other microorganisms
In cells and tissues, human somatic cells or allogeneic human
iPS(-like) cells that serve as raw materials, inactivate and eliminate
bacteria, fungi, viruses, and other microorganisms if necessary and
whenever possible, to such an extent that the procedures do not
have any effect on the cell viability, phenotype, genetic traits,
speciﬁc functions, quality, or other characteristics of the cells and
tissues serving as raw materials. State the suitability of the mea-
sures, procedures, and evaluation methods employed, if any.
(3) Tissue homogenization, cell separation, isolation of speciﬁc
cells, and other techniques
Describe themethods for homogenization of a tissue, separation
of somatic cells, isolation of speciﬁc somatic cells, and methods for
washing of these cells and tissues (and other methods) in order to
generate the iPS(-like) cells (the procedures that are performed at
the early stages of manufacture of the iPS(-like) cell-based products
from collected cells and tissues). Upon isolating speciﬁc somatic
cells, establish identiﬁcation methods for the cells.
(4) Establishment of allogeneic human iPS(-like) cell lines
Establish an allogeneic human iPS(-like) cell line after having
determined as thoroughly as possible the genetic background of the
donor. Describe the methods used up until the establishment of
iPS(-like) cells from somatic cells that serve as the rawmaterial and
describe, as thoroughly as possible, the appropriateness of the
methods.
Identify critical quality attributes of the cells, and set acceptance
criteria for them. Demonstrate the number of passages or cell di-
visions within which the cells can proliferate while maintaining
their quality in terms of the criteria speciﬁed (refer to Chapter II-4-
I-3)).
(5) Establishment of an intermediate cell line derived from
allogeneic human iPS(-like) cells
It should be noted that in some cases, the establishment of a cell
line (intermediate cell line) as an intermediate product may be
important for the stable manufacture of a safe ﬁnal product and for
scientiﬁc validity of the procedure. When such ameasure is chosen,
explain its advantages and appropriateness. If a cell line that ex-
hibits a different phenotype is established in stages, describe the
methods (for example, methods for induction of differentiation,
isolation, culturing, and cell line establishment of the target cells,
the media, culture conditions, culture duration, and the yield at
each stage) until establishment of each respective cell line and
explain their appropriateness to the extent possible.
To maintain the stability and consistency of the quality of the
intermediate cell line, identify critical quality attributes of the cells
(for example, cell population purity, morphological features,
phenotype-speciﬁc markers, karyotype, cell growth properties, and
differentiation potency) and set acceptance criteria. Demonstrate
the number of passages or of cell divisions within which cells can
proliferate while maintaining their quality in terms of the criteria
speciﬁed. Although comprehensive cell characterization is always
desirable, it is recognized that quantitative limits on samples or
technological limits maymake it difﬁcult to perform the study fully.
If this is the case, it is acceptable to perform a limited study to the
extent possible.
If establishing and utilizing a cell bank from an intermediate cell
line in accordance with the above, refer to point (7).
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the ﬁnal product and serve as an active ingredient
Describe the methods, either directly from an allogeneic human
iPS(-like) cell line or an intermediate cell line derived from human
iPS(-like) cells, that are used to prepare the cells that serve as the
active ingredient in the ﬁnal product. Describe the induction of
differentiation, isolation, and culturing of the desired cells, the
media, culture conditions, culture duration, yields of the desired
cells, and other characteristics at each step. Describe the appro-
priateness of each method, to the extent possible.
(7) Establishment of cell banks
When a cell bank is established at any stage during the process
of manufacturing allogeneic human iPS(-like) cell-based products,
describe the details of the rationale for preparing the cell banks; the
methods used to prepare the cell banks, characterization of the cell
banks; and storage, maintenance, control methods, and renewal
methods as well as any other processes and tests performed and
provide justiﬁcation for each. Refer to “Derivation and Character-
ization of Cell Substrates Used for Production of Biotechnological/
Biological Products” (Pharmaceutical Notiﬁcation No. 873, Evalua-
tion and Licensing Division, Pharmaceutical and Food Safety Bu-
reau, Ministry of Health, Labour andWelfare of Japan, July 14, 2000)
and other relevant documents. It is acceptable to omit a portion of
the test items, if the cells have been properly evaluated at an up-
stream step in the process (for a valid reason).
(8) Measures to prevent erroneous sampling (mix-up) and
cross-contamination during the manufacturing process
It is extremely important to prevent erroneous sampling and
cross-contamination during the manufacturing process when
manufacturing human iPS(-like) cell-based products. Therefore,
clearly describe preventive measures in the control process.4.2.3. Characterization of cells that comprise a principal component
of a ﬁnal product and serve as an active ingredient
Analyze various attributes of the cells, such as cell population
purity, to control contamination with undifferentiated or
nontarget cells, cell viability, morphological characteristics,
growth characteristics, biochemical markers, immunological
markers, distinctive substances produced by cells, karyotype, dif-
ferentiation potency, and other appropriate genotypic and
phenotypic markers of the cells that makeup a principal compo-
nent of the ﬁnal product. Additionally, characterize the cells in
relation to biological functions, where necessary. Furthermore, to
evaluate the appropriateness of the culture duration and stability
of the cells, use appropriate markers of cell characteristics to prove
the absence of unintended changes in cells cultured beyond the
proposed culture period. It is acceptable to perform these studies
preliminarily, using test samples obtained from donors in place of
the real products that will be prepared for a clinical trial. These
results can be used to identify the critical cell characteristics that
should be used when applying the real product to the treatment of
a patient. Although comprehensive cell characterization is always
desirable, quantitative limits on samples or technological limita-
tions may prevent the full characterization. In this case, it is
acceptable to perform a limited study to the extent possible. When
cell processing, such as growthwithin the body, is anticipated after
clinical application, clearly demonstrate the functions expected
using the passage number or number of cell divisions based on the
speciﬁed criteria.4.2.4. The form and packaging of the ﬁnal product
The form and packaging of the ﬁnal product shall ensure the
quality of the ﬁnal product.
4.2.5. Storage and transport of the ﬁnal product
If an intermediate or ﬁnal product must be stored and trans-
ported, the storage procedure and duration, the containers used for
transport, and the transportation procedure (including tempera-
ture control) shall be stated and their appropriateness clearly
indicated (refer to Section 5 (Chapter III)).
4.2.6. Consistency of the manufacturing procedure
To assess the consistency of the manufacturing process using
each product (each lot) obtained from different production runs,
determine whether they differ signiﬁcantly with respect to the
number of cells, cell viability, and cell characteristics (such as
relevant markers of a phenotype and/or genotype, functional
characteristics, and the percentage of the desired cells), considering
the application methods and intended use of the product. It is
acceptable to use test samples in place of the real products that will
be prepared for a clinical trial. Evaluation using intermediate
products may provide an accurate explanation of the suitability of
the cells and tissues used as raw materials and the validity of the
manufacturing process until the point of production of the inter-
mediate products and may serve as an appropriate guidepost
leading up to the ﬁnal product. Therefore, it may be reasonable to
adopt such an approach, where necessary and appropriate.
When the duration of the cryopreservation or cell cultivation
portion of the manufacturing process is lengthy, perform sterili-
zation tests and other relevant procedures at consistent intervals to
conﬁrm that sterility has been preserved.
4.2.7. Changes in the manufacturing process
If the manufacturing process is altered at some point during
development, and if test results that are obtained using products
manufactured prior to the change are to be used in the application
for clinical-trial or regulatory approval, demonstrate the compa-
rability of the products manufactured before and after the
alteration.
4.3. Quality control of the ﬁnal product
4.3.1. Introduction
The overall quality control strategy for allogeneic human iPS(-
like) cell-based products includes speciﬁcations (a set of accep-
tance criteria and analytical procedures) for ﬁnal products, quality
control of raw materials for each therapeutic application to each
patient, veriﬁcation of the appropriateness of the manufacturing
process and maintenance of its consistency as well as proper
quality control of intermediate products, if any. One of the most
critical issues in case of iPS(-like) cell-based products is the mea-
sure to ensure the absence of contamination of the cells by undif-
ferentiated cells other than the desired cells. Veriﬁcation of the
absence of contamination by nontarget undifferentiated cells is
desirable, as much as possible, at the intermediate-product stage.
Speciﬁcations will differ among ﬁnal products depending on the
type and properties of the desired cells and tissues, manufacturing
methods, intended clinical use, and method of clinical application
of each product, stability and available test methods. These differ-
ences shall be taken into consideration when setting acceptance
criteria and analytical procedures. In addition, speciﬁcations shall
be set and justiﬁed from the standpoint of achieving the purpose of
quality control as a whole, by taking into consideration the mutu-
ally complementary relationships among 1) veriﬁcation of the
suitability of the manufacturing process, 2) the method for
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and intermediate products. The purpose of the assessment for
initiating clinical trials is to conﬁrm that the product in question is
unlikely to pose signiﬁcant quality/safety problems for use in
investigational clinical trials. Therefore, it is possible to set provi-
sional speciﬁcations with allowance for some variation, based on
values measured using a few test specimens, as long as one can be
certain of the relationships between the results of clinical tests and
such quality attributes after clinical trials. However, testing for
sterility and the absence of mycoplasma is essential. It should be
noted that the quality control strategy, including speciﬁcations,
shall be enriched and developed in tandem with the progress of
clinical trials.4.3.2. Quality control of the ﬁnal product
Refer to the general quality control parameters and tests
described below, set appropriate speciﬁcations for the ﬁnal prod-
uct, and provide the rationale for these speciﬁcations.
Set appropriate acceptance criteria and test procedures for in-
dividual products that do not comprise a lot as well as for individual
products that do comprise a lot because each lot is typically a unit
subject to quality control.
(1) Cell number and cell viability
The number and viability of cells that are active ingredients in
the ﬁnal product, or in an appropriate intermediate product, if
required, should be determined. At the beginning of the clinical
trial, it is acceptable to set provisional acceptance criteria based on
actual measured values obtained for a small number of test
samples.
(2) Tests of identity
Conﬁrm that the cells are the intended target cells using
markers for critical cell characteristic(s) selected from the
biochemical markers, morphological characteristics, immunolog-
ical markers, characteristic products, and other appropriate geno-
types or phenotypes of the intended target cells and tissues.
(3) Tests of purity
To test the purity of the cell population in a ﬁnal product, set
the test parameters, test methods, and acceptance criteria for
evaluating and controlling nontarget cells, such as undifferenti-
ated cells, cells exhibiting abnormal growth, transformed cells as
well as the presence of any other contaminating cells, considering
the origin of the target cells and tissues, the culture conditions,
and other parameters of the manufacturing process, such as
quality control of intermediate products. At the beginning of the
clinical trial, it is acceptable to set provisional acceptance criteria
based on actual measured values obtained for a small number of
test samples.
(4) Tests for cell-derived undesirable physiologically active
substances
Specify the appropriate tests for determining the permissible
dose limits of any potential undesirable physiologically active
substances that are derived from the target cells, if the presence of
such substances in the product is presumed to clearly impact the
safety of the patients. At the beginning of the clinical trial, it is
acceptable to set provisional acceptance criteria based on actual
measured values obtained for a small number of test samples.(5) Tests for process-related impurities
For substances that may be present in the ﬁnal product, for
instance, as contaminants, residues, newly generated products or
degradation products; that potentially originating from raw mate-
rials, noncellular components, media ingredients (including feeder
cells), chemical reagents, or any other process-related materials;
and that may have deleterious effect on the quality and safety (for
example, albumin derived from fetal calf serum and antibiotics), it
is necessary to 1) prove that the substance is not present in the ﬁnal
product using the results of process evaluation for the elimination
of the substance or the results of in-process control of the sub-
stance or 2) establish appropriate tests to control the amount of the
substance in the ﬁnal product within permissible levels. When
selecting substances to be tested and setting their acceptance
criteria, their suitability should be explained and justiﬁed.
At the beginning of the clinical trial, it is acceptable to set pro-
visional acceptance criteria based on actual measured values ob-
tained for a small number of test samples.
(6) Sterility tests and tests for the absence of mycoplasma
The sterility of the ﬁnal product should be adequately assessed
to ensure sterility throughout the entire manufacturing process
using test samples. The sterility (negative results of tests for com-
mon bacteria and fungi) of the ﬁnal product should be demon-
strated in tests before use in a patient. Appropriate tests conﬁrming
the absence of mycoplasma should also be carried out. A validated
nucleic-acid ampliﬁcation test can be used. If the results of the
sterility and other tests of the ﬁnal product can be obtained only
after administration to the patient, the proper measures for dealing
with the potential lack of sterility should be established before-
hand. In such cases, the intermediate products must be demon-
strated to be sterile, and sterility should be strictlymaintained in all
processes leading up to the ﬁnal product. If a product from the same
facility and same process has already been used in patients, its
sterility must be conﬁrmed by testing it in all patients. If complete
closure (hermetic seal) of an individual lot of the product has been
ensured, tests using only representative samples are sufﬁcient.
When tests must be conducted for each clinical application and if
the results of sterility and other tests can be obtained only after
administration to the patient, the decision on whether the clinical
application should proceed will be determined based on the most
recent data. However, even in this case, sterility tests and other
tests shall be performed on the ﬁnal product.
It is desirable that every effort be made to avoid the use of antibi-
otics in cell culture systems;however, if theyareused, adoptmeasures
to ensure that the antibiotics do not inﬂuence the sterility tests.
(7) Endotoxin tests
Perform an endotoxin test, considering the impact of a potential
contaminant in the samples. The acceptance criteria do not
necessarily depend on the actual measured values. It is recom-
mended to set acceptance criteria considering the safety ranges
given in the Japanese Pharmacopoeia and/or any other relevant
compendia based on a single dose of the ﬁnal product. Endotoxin
testing can be established as an in-process control test; however, in
such cases, specify criteria, including validation results, and provide
the justiﬁcation.
(8) Virus tests
Use a titer test to detect viruses in the intermediate and ﬁnal
product and conﬁrm that administration of the allogeneic human
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tient, when using cells that are not banked in either rawmaterials or
manufacturing processes and are from donors not cleared of infec-
tion in the window period, and in the cells during manufactures
process HBV, HCV, HIV, or HTLV can propagate. If components of
biological origin are used in the manufacturing process, it may be
necessary to consider performing tests on the ﬁnal product for vi-
ruses originating from those components. However, whenever
possible, it is preferable to determine that there is no contamination
via testingor process evaluation at theupstreamstage, including the
original component.
(9) Speciﬁc biological tests
In some instances, it will be necessary to consider speciﬁc (quan-
titative orqualitative) biological testing that takes into account the cell
type, intended clinical use, or distinctive characteristics of the cells. At
the beginning of the clinical trial, it is acceptable to set provisional
acceptance criteria based on measured values obtained for a small
number of test samples.
(10) Potency assay
If the secretion of a speciﬁc physiologically active substance
from the cells or tissues is responsible for the efﬁcacy or the
essential effect of an allogeneic iPS(-like) cell-based product during
its intended clinical use, establish test parameters and/or accep-
tance criteria related to this substance in order to demonstrate the
intended effect. Set acceptance criteria for potency or quantitation
of a gene expression product secreted from the cells when a
transgene was introduced. At the beginning of the clinical trial, it is
acceptable to set provisional acceptance criteria based onmeasured
values obtained for a small number of test samples.
(11) Mechanical compatibility tests
For products that require a certain degree of mechanical
strength, set acceptance criteria to conﬁrm mechanical compati-
bility and durability that take into account the site of application. At
the beginning of the clinical trial, it is acceptable to set provisional
acceptance criteria based on actual measured values obtained for a
small number of test samples.5. Chapter III. Stability of allogeneic human iPS(-like) cell-
based products
Taking into full consideration the storage and distribution
periods and the storage form, perform suitable stability testing
on allogeneic human iPS(-like) cell-based products and/or crit-
ical intermediate products based on cell viability, potency, and
other characteristics to establish storage methods and expiration
date, and provide justiﬁcation for their suitability. In particular,
when freezing and thawing are involved in the storage and use
of the products, conﬁrm that the freezing and thawing processes
do not affect the stability or acceptance criteria of the product.
Where necessary and possible, it is recommended to conduct
stability studies on the products whose manufacturing or stor-
age periods exceed the normal periods, in order to conﬁrm, as
thoroughly as possible, the limits of stability. This does not apply
if a product will be used immediately after production.
If an allogeneic human iPS(-like) cell-based product will be
transported, the relevant transportation vessels and transportation
procedures (such as thermal management) shall be set and their
appropriateness justiﬁed.6. Chapter IV. Preclinical safety testing of allogeneic human
iPS(-like) cell-based products
Relevant animal tests and/or in vitro tests may be performed to
elucidate concerns about the safety of an allogeneic human iPS(-
like) cell-based product when it is scientiﬁcally reasonable and
technically possible.
Safety concerns about noncellular constituents and process-
related impurities should be resolved, as much as possible, using
physicochemical analyses and not animal testing. In addition, the
presence of undifferentiated cells in the ﬁnal product and their po-
tential to cause ectopic tissue formation, tumorigenicity, or malig-
nant transformationarea safetyconcern. Therefore, it is necessary to
reduce the risk of contaminationwith such cells asmuch as possible
via thorough analysis at the cell bank and/or at an intermediate-
product stage or by developing and utilizing methods that effec-
tively separate, remove, and/or inactivate these contaminating un-
differentiated cells from the target cells during the manufacturing
process. Furthermore, the administration route for the target cells
may be selected to aid in the minimization of the safety risks.
Animal testing of products of human origin does not always
yield meaningful results. Thus, there may be a scientiﬁc rationale
for preparing product models of animal origin and testing on
appropriate experimental animals if more useful information
may be obtained. In such a case, consider conducting tests on
suitable animal models for each target disease (For example,
monkeys may be suitable for neurological diseases, while pigs
and/or dogs may be suitable for cardiovascular diseases.). How-
ever, because the use of identical procedures in nonhuman ani-
mals will not necessarily yield cell groups that possess
characteristics identical to those of cells that constitute an allo-
geneic human iPS(-like) cell-based product and because a prod-
uct of animal cell origin that was manufactured using identical
processing, including culture conditions, will not necessarily be
comparable to a human cell-based product, careful feasibility
studies are required beforehand when adopting, conducting, and
evaluating such studies. When conducting animal experiments
using iPS(-like) cell-based products obtained from nonhuman
animal species, explain the suitability of the extrapolation.
Depending on the case, consider test systems that employ cells
and clearly explain the appropriateness of the test system when
conducting tests using this kind of approach.
The examples below present points to consider when conﬁrm-
ing the preclinical safety of a product. These are merely examples
for illustration and are not meant to suggest that tests should be
conducted without a rational basis. Conduct necessary and appro-
priate tests, taking into account the characteristics of the product
and intended clinical use, and other parameters, and evaluate and
discuss the results in a comprehensive manner.
1. For cells expanded beyond the deﬁned limit for cultivation
(duration of culture, the population doubling level, or the pas-
sage number of the cells) for routine production, clearly
demonstrate that undesirable alterations other than the inten-
ded transformation and abnormal proliferation of nontarget
cells have not occurred.
2. It may be necessary to conduct quantitative assays of particular
physiologically active substances produced by the cells and
tissues and to discuss their effects when given to patients. In
some cases, signiﬁcant amounts of active substances including
cytokines and growth factors would be produced by the cells,
potentially resulting in undesirable effects on the patients.
3. Examine and discuss the potential effects and safety conse-
quencesof theproducton thehealthycells andtissuesof apatient.
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consequences of the formation of ectopic tissue by cells in the
product and/or contaminating undifferentiated cells when the
product is given to the patients. Discuss in a comprehensive
manner, taking into account the type and characteristics of the
product, the route of administration, target diseases, appropri-
ateness of the test system, and other characteristics.
5. Investigate and discuss the possibility and safety of undesirable
immunological reactions to the product and/or expression
product of a transgene and the relevant safety concerns.
6. Using an appropriate animal model or other system, investi-
gate and discuss the possibility of tumor formation including
benign tumors and/or malignant transformation of cells in the
ﬁnal product or in an intermediate product. These studies
should be performed suitably by taking into account the type
and characteristics of the product, number of cells and route of
administration, mode of application (e.g., cell sheet or cell
suspension), cell engraftment site, target diseases, appropri-
ateness of the tests systems, and other characteristics. If there
is a possibility of tumorigenicity or malignant transformation,
provide justiﬁcation for the use of the product in question and
its rationale, considering the relationship with the anticipated
efﬁcacy. (Note: The most important aspect of a tumorigenicity
test is to accurately assess the tumorigenicity of a ﬁnal product
that will be used in patients. However, it is conceivable that
tumorigenicity will need to be evaluated using cells from an
intermediate product because the cells comprising the ﬁnal
product cannot be used for various reasons, such as the
impossibility to obtain a sufﬁcient number of cells. Further-
more, in tumorigenicity tests using animal models, various
conditions such as cell dispersion and cell adhesion to the
scaffolding, cell density, and administration site are not always
identical to those for the ﬁnal product. Sensitivity may differ
depending on the species, strain, and immunological state of
the animal. The tumorigenicity of the ﬁnal product should be
evaluated with comprehensive consideration of these cir-
cumstances. The risks to the patient arising from tumorige-
nicity of the ﬁnal product should be rationally evaluated based
on the balance between any risks and the beneﬁts to the pa-
tient as a result of treating the disease.)
7. If an exogenous gene is introduced into cells during the
manufacturing process, and if it may function or remain as a
residue in the ﬁnal product, conduct tests in accordance with
the “Gene Therapy Pharmaceutical Guidelines.” In particular, if
viral vectors are used, determine quantitatively the potential
presence of any replication-competent viruses and provide
justiﬁcation for the test employed. Describe the safety of the
transgene and its products based on their characteristics. For
cells, discuss the possibility of changes in cell growth or the risk
of tumor formation including benign tumors and malignant
transformation. Whenever a vector, which may get inserted into
a chromosome, is used, consider the necessity of evaluating
possible occurrence of abnormal proliferative characteristics
and/or tumorigenicity due to an insertion mutation in the cells
and the necessity of implementing long-term follow-up for
clinical applications.
8. Consider conducting rationally designed general toxicological
tests if the product, including an animal-derived model of
product, is easy to obtain, and if doing so will generate useful
information regarding its clinical application.
When conducting general toxicological tests, refer to the
“Guidelines for Toxicology Studies on Pharmaceuticals,” which
is an appendix to the document entitled “Guidelines on Toxi-
cology Studies Required for Regulatory Approval for theManufacture or Import of Pharmaceuticals” (Drug Evaluation
Notiﬁcation 1:24, issued September 11, 1988, New Drug Divi-
sion/Evaluation and Licensing Division, Pharmaceutical Affairs
Bureau, Japanese Ministry of Health and Welfare).7. Chapter V. Studies supporting the potency or efﬁcacy of
allogeneic human iPS(-like) cell-based products
1. A well-designed study using experimental animals and/or cells
should be performed in order to demonstrate the functional
expression, sustainability of an effect, and/or anticipated clinical
efﬁcacy (proof of concept) of an allogeneic human iPS(-like) cell-
based product to the scientiﬁcally reasonable and technically
possible extent.
2. For transgenic cells, demonstrate the expression efﬁciency,
sustainability of expression, and biological activity of desired
products derived from the (trans)gene. Discuss rationale of the
transgene expression products as active ingredients for antici-
pated clinical efﬁcacy (proof of concept) of the allogeneic human
iPS(-like) cell-based product in question.
3. Where appropriate models of products derived from processing
of animal iPS(-like) cells and/or animal models of a disease are
available, use them to study the potential therapeutic efﬁcacy of
the product.
4. At the beginning of the clinical trial, detailed experimental
studies will not necessarily be required if the potency or efﬁcacy
of the therapy employing the product in question is expected to
be markedly superior to other therapeutic methods, and if this
can be justiﬁed by means of scientiﬁc literature and/or other
available information.8. Chapter VI. Pharmacokinetics of allogeneic human iPS(-
like) cell-based products
1. Pharmacokinetic studies of the internal behavior of cells/tissues
that constitute the ﬁnal products or expression products of
transgenes (these studies may include assessment of the ab-
sorption and distribution in experimental animals), should be
performed to the technically possible and scientiﬁcally reason-
able extent. Therefore, these studies are expected to estimate
the survival of cells/tissues administered to patients and the
duration of their effects and to determine whether the intended
efﬁcacy is successfully achieved. (Note: Testing methods may
include histological studies, human Alu sequences ampliﬁcation
by polymerase chain reaction (Alu-PCR), magnetic resonance
imaging (MRI), positron emission tomography (PET), single
photon emission computed tomography (SPECT), and
bioimaging)
2. Clarify, using animal studies, the rationale for the administration
method for the allogeneic human iPS(-like) cell-based products.
In particular, extrapolate from animal experiments, the systemic
distribution of cells after systemic administration and discuss
the distribution from the point of view of clinical usefulness.
(Note: Although it is unclear exactly where the cells adhere with
each administration route, it is assumed that local administra-
tion is preferable to systemic administration. However, if the
beneﬁts to patients can be explained in a rational manner, it is
acceptable to use systemic administration. In any case, an
administration method that minimizes distribution of an iPS(-
like) cell-based product to organs other than the target organ
is preferred. Even if the cells localize to a site other than the
intended transplantation site, an administration method is
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caused by osteogenesis of some types of cells that ectopically
locate to the heart is an example of an adverse effect that can
result from ectopic differentiation.)
3. When the cells or tissues are directly applied or alternatively
targeted to a speciﬁed site (e.g., tissue) where they can be ex-
pected to perform their actions, clarify the localization, and
discuss the effect of the localization on the efﬁcacy and safety of
the product.9. Chapter VII. Preliminary analysis of clinical trials
Themain purpose of the present guideline is to address points to
consider for evaluating the quality and safety of allogeneic human
iPS(-like) cell-based products at the time of application for mar-
keting authorization and at the beginning of investigational clinical
trials. In the latter case, it is necessary to determine whether any
quality or safety problems exist that might pose an obstacle to
initiation of human clinical trials, taking into consideration the
product's clinical usefulness. Thus, quality and nonclinical safety
evaluation for the decision to initiate the investigational clinical
trials of the product in question should be conducted with refer-
ence to the points outlined below. Any known risk factors associ-
ated with the product's quality and safety should be eliminated as
much as possible, using up-to-date science and technology, and the
scientiﬁc appropriateness should be clearly described. Any
remaining risks should be weighed against the risks associated
with not performing the trials on patients that suffer from diseases
that are serious and life-threatening, that involve marked func-
tional impairment, or a marked decrease of quality of life resulting
from the loss of a certain degree of a physical function or form, and
for which existing therapies have limitations and do not result in a
cure. Furthermore, it is also important to entrust the patient with
the right to make a decision after receiving all of the available in-
formation, including all information on identiﬁed/presumed risks
and anticipated beneﬁts.
1. Target disease.
2. Target subjects and patients who should be excluded as
participants.
3. Details of the therapy to be performed on the subjects, including
the application of allogeneic human iPS(-like) cell-basedproducts and drugs used concomitantly. (Note: If it is antici-
pated that drugs will be coadministered in order to maintain,
enhance, and/or induce the function of the administered or
transplanted cells, verify the intended activity of the drugs
either in vitro or in vivo.)
4. Appropriateness of conducting the clinical trials in light of
existing therapeutic methods.
5. Plan for explaining the clinical trial to the patients, including the
currently known risks and beneﬁts of the product.
Clinical trials should have an appropriate study design and
clearly speciﬁed endpoints. They should be designed based on the
desired cells/tissues, target disease, and method of application.Disclosures
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